How does pembrolizumab kill cancer cells?
Medically reviewed by Leigh Ann Anderson, PharmD. Last updated on Nov 16, 2020.
Pembrolizumab (brand name: Keytruda) is a type of immunotherapy drug known as an Immune Checkpoint Inhibitor. It blocks the PD-1 (programmed death receptor-1) pathway to help prevent cancer cells from hiding from the immune system. Pembrolizumab is not a chemotherapy drug or radiation treatment and does not attack cancer cells directly.
Pembrolizumab treats many different types of cancers, including lung cancer, melanoma (a type of skin cancer), and triple negative breast cancer.
Here’s how it works:
- Checkpoint inhibitors like pembrolizumab help to boost your own immune system response against cancer.
- T-cells (also called T-lymphocytes) are a type of white blood cell. Normally, when cancer cells circulate in your body, your immune system activates T-cells to target and destroy these cells. T-cells help your body to detect and fight infections, disease and play an important role in fighting cancer, too.
- But some cancer cells can avoid detection by attaching to receptor sites found on the T-cells known as PD-1. This prevents the activation of the T-cell which normally would target and destroy the cancer. The cancer cells can then multiply and spread.
- When a PD-1 immune checkpoint inhibitor such as pembrolizumab (Keytruda) is given, it binds to the PD-1 receptor on the T-cell. This helps to block the cancer cells from linking to and inactivating the T-cells. Pembrolizumab can allow re-activation of the immune system T-cells to help fight off the cancer.
- While having an effect on the tumor, this could also affect normal healthy cells. It is important to understand the possible side effects with this drug. Discuss this information with your doctor.
See pembrolizumab side effects (in more detail)
Pembrolizumab (Keytruda) is a type of immunotherapy drug known as an Immune Checkpoint Inhibitor. It blocks the PD-1 (programmed death receptor-1) pathway to help prevent cancer cells from hiding from the immune system.
Pembrolizumab binds to the PD-1 receptor on the T-cell and helps to block the cancer cells from linking to and inactivating the cancer-fighting T-cells. While having an effect on the tumor, this could also affect normal healthy cells.
Pembrolizumab is not a chemotherapy drug or radiation treatment and does not attack cancer cells directly.
This is not all the information you need to know about pembrolizumab for safe and effective use. Review the full pembrolizumab (Keytruda) product information here, and discuss this information with your doctor or other health care provider.
- Keytruda [product information]. Merck & Co. Whitehouse Station, NJ. Accessed Oct. 28, 2020 at https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf
- Keytruda.com (online). Clinical trial results. Merck & Co. Accessed Oct. 28, 2020 at https://www.keytruda.com/.
Related Medical Questions
- What is the difference between Opdivo and Keytruda?
- What is the success rate of Keytruda?
- Is Keytruda covered by Medicare / Medicaid?
- Pembrolizumab vs. nivolumab: how do they compare?
- How does pembrolizumab affect the immune system?
- What type of cancer is pembrolizumab used for?
- Is lenvatinib / pembrolizumab used in endometrial cancer?
Related Support Groups
- Keytruda (14 questions, 48 members)
- Cancer (100 questions, 595 members)
- Non-Small Cell Lung Cancer (24 questions, 60 members)
- Hepatocellular Carcinoma (22 questions, 21 members)
- Renal Cell Carcinoma (22 questions, 92 members)
- Melanoma (21 questions, 46 members)
- Gastric Cancer (15 questions, 12 members)
- Endometrial Cancer (14 questions, 32 members)
- Small Cell Lung Cancer (14 questions, 20 members)
- Urothelial Carcinoma
- Colorectal Cancer (13 questions, 50 members)
- Melanoma - Metastatic (11 questions, 27 members)
- Head and Neck Cancer
- Esophageal Carcinoma
- Squamous Cell Carcinoma
- Cervical Cancer
- Hodgkin's Lymphoma
- Solid Tumors
- Merkel Cell Carcinoma
- Primary Mediastinal Large B-cell Lymphoma